In this must-see market update, Larry Williams returns with timely stock market analysis, trading insights, and macroeconomic forecasts. Discover what’s next for the Federal Reserve, interest rates, and inflation — and how it could impact top stocks like Tesla (TSLA), Nvidia (NVDA), Apple (AAPL), and consumer staples (XLP).
This video originally premiered on May 27, 2025. Watch on StockCharts’ dedicated Larry Williams page!
Previously recorded videos from Larry are available at this link.
Former Olympic champion gymnast Mary Lou Retton was arrested earlier this month in West Virginia for DUI.
She was later released after posting $1,500 bond.
Retton was in the news last year when her daughter revealed on social media that the 1984 Olympic all-around champion was ‘fighting for her life’ with ‘a very rare form of pneumonia’ and was not insured.
That led to a flood of donations totaling over $450,000 – but also to questions about basic details of Retton’s illness, whether or not she had health insurance and exactly how the money collected was being spent.
Retton did agree to an interview with NBC’s ‘Today Show’ in January 2024, appearing with an oxygen tube in her nose and describing a harrowing, month-long hospital stay, including a moment when ‘they were about to put me on life support,’ she said.
Follow more athlete news: Sign up for USA TODAY’s Sports newsletter.
Retton’s daughter, McKenna Kelley, told USA TODAY Sports at that time Retton could not get affordable health care because of pre-existing conditions, which she said include ‘over 30 orthopedic surgeries, including four hip replacements.’
Retton later told NBC in the interview that she was able to get medical insurance.
Retton’s family said that any funds remaining after her medical expenses were paid would be donated to a charity of her choice. But no further information was ever revealed.
The Edmonton Oilers are one win away from a return trip to the Stanley Cup Final.
The Oilers defeated the Dallas Stars, 4-1, on Tuesday night to take a 3-1 series lead in the Western Conference finals.
Dallas had a strong first period, outshooting the Oilers 16-10, but the Stars couldn’t get a shot past Edmonton goaltender Stuart Skinner and found themselves down 1-0 thanks to a Leon Draisaitl power-play goal.
From there, the Oilers started to put the clamps on.
The second period was much more even, with the Oilers putting up 10 shots to the Stars’ nine. Dallas tied the game at 6:57 of the second on a Jason Robertson power-play goal but the Oilers got another power-play goal a little over two minutes later to take the lead for good.
That 2-1 lead held up because Edmonton put on a defensive masterclass in the third period.
The Oilers held the Stars to just four shots while putting up 13 themselves in the final frame. Edmonton couldn’t beat Jake Oettinger (30 saves) again, but it finally sealed the game with two empty-net tallies.
Skinner stopped 28 of the 29 shots he faced.
Game 5 is Thursday night in Dallas (8 p.m. ET, ESPN).
“They’re going to be desperate, we know that, but we got to obviously match that,’ Draisaitl told ESPN, looking ahead to Game 5.
Another empty-net goal for the Oilers at 19:10, this one from long range from Adam Henrique.
That should do it.
Kasperi Kapanen’s empty-net goal gives the Oilers a two-goal lead with just over two minutes to go.
Some redemption for Corey Perry.
His penalty led to Dallas’ equalizing goal, but he gives the Oilers the lead again with yet another power-play strike at 9:20.
Jason Robertson gets the Stars on the board with their 21st shot of the game.
His power-play goal at 6:57 levels things after the Oilers killed off the Stars’ first two power-play opportunities.
Edmonton will be down a key forward for the final two periods of Game 4.
Zach Hyman went to the locker room in the first period and never returned following a check from Mason Marchment.
Dallas didn’t score in the first period and Stuart Skinner is mostly to thank for that. The Stars peppered the Oilers’ goalie with 17 shots but he stopped them all.
The Stars will have nearly a full power play to work with on fresh ice to start the second period after Vasily Podkolzin was called for roughing at 19:52.
Edmonton is on the board first, courtesy of a Leon Draisaitl power-play goal.
The Rocket Richard winner potted his seventh goal of the playoffs in signature fashion: with a one-timer from the right faceoff circle. Ryan Nugent-Hopkins and Corey Perry got the assists on the goal at 11:23 of the first.
Game 4 of the Stars-Oilers series is Tuesday, May 27 at 8 p.m. ET in Edmonton, Alberta.
Time: 8 p.m. ET/6 p.m. local
Location: Rogers Place (Edmonton, Alberta)
TV: ESPN
Stream: ESPN+, Fubo
Get the latest sports news delivered conveniently to your inbox. Sign up for USA TODAY Sports’ daily newsletter now!
The New York Knicks are in a 3-1 hole in the Eastern Conference finals, and they may have to attempt a series comeback without Karl-Anthony Towns.
New York’s big man was injured late in the Game 4 loss to the Indiana Pacers Tuesday. With just more than two minutes left, Pacers forward Aaron Nesmith was driving toward the basket when Towns attempted a close out. The two players collided and Towns’ left knee bumped into Nesmith’s right knee. Towns immediately grabbed at his knee and went down to the floor in visible pain.
Towns was able to get up and had a noticeable limp as he walked to the bench. Despite being slowed down by the injury, Towns remained in the contest. He finished with 24 points, 12 rebounds and three assists.
Knicks coach Tom Thibodeau didn’t know the extent of the injury following the defeat but he will be examined before Game 5.
‘He was able to go back in, so that’s a good sign. We’ll see where he is after he gets evaluated,’ Thibodeau said.
In 2024, Towns’ suffered a torn left meniscus that forced him to miss a month of action before he returned before the playoffs.
Towns has had a key role for a New York team playing in the Eastern Conference finals for the first time since 2000. He has averaged 21.3 points per game this postseason, second-most for the Knicks behind Jalen Brunson. He’s also averaging a team-high 11.4 rebounds per game in the playoffs.
If it weren’t for Towns, the season could already be over for New York. He played a key role in the Game 3 comeback by scoring 20 points in the fourth quarter as the Knicks came back from 20 points down to win their first game of the series.
New York will be playing to keep its season alive with Game 5 at Madison Square Garden on Thursday.
Former NBA player and six-time All-Star Shawn Kemp pleaded guilty to an assault charge after he shot two men inside a Washington state mall parking lot in 2023.
Kemp pleaded guilty to second-degree assault in Pierce County Superior Court on Tuesday, according to court documents obtained by USA TODAY Sports. Kemp was initially charged with one count of first-degree assault with a firearm enhancement, but prosecutors amended the charges last week to add a second first-degree assault charge with a firearm enhancement, as well as drive-by shooting. Kemp could have served a lengthy prison sentence had he been convicted on the original charges.
With the guilty plea, prosecutors recommended Kemp be sentenced to nine months in jail, one year of community service and to pay restitution. He will be sentenced on Aug. 22, when both sides of the case will be able to argue for their preferred sentence, according to the Pierce County Prosecuting Attorney’s Office. Officials said the standard range for the offense with someone with no criminal history is three to nine months.
This was an “open” plea agreement, so both sides will be free to argue for their preferred sentence on Aug. 22. What Mr. Kemp pleaded guilty to is a felony and a strike offense.
‘Shawn is committed to moving forward in a positive direction,’ Kemp’s attorney Tim Leary told The Seattle Times. ‘He was presented with an offer from the state that allows him to take responsibility, but I think also recognizes the self-defense nature of how this transpired.’
The incident occurred on March 8, 2023 when Kemp said his car was broken into, and several items such as his phone and memorabilia from his basketball career were stolen, according to court documents. Kemp was able to track his phone to a Toyota 4Runner and tried to talk to the driver about his missing phone. Later, he tracked his phone to the Tacoma Mall, where he saw the same 4Runner as before, the defense stated.
Court documents said a man in the back seat of the 4Runner fired a gun at Kemp, who then fired back at the vehicle. The two occupants of the 4Runner were not injured but the vehicle was as it fled.
Kemp was arrested in connection to the incident and was released a day later. The two men, ages 39 and 35, in the 4Runner are currently serving prison sentences due to other cases.
A first-round selection in the 1989 NBA Draft, Kemp became a star for the Seattle SuperSonics, playing eight seasons with the team while forming an on-court combo with Gary Payton. He also had stints with the Cleveland Cavaliers, Portland Trail Blazers and Orlando Magic during the course of his 14 seasons in the league.
Philadelphia Phillies star Bryce Harper was removed early from Tuesday’s matchup against the Atlanta Braves after he was hit in the elbow by a pitch.
The injury occurred in the bottom of the first inning when a 95 mph fastball from Braves pitcher Spencer Strider drilled Harper, who was immediately in pain. After trying to walk it off, he went down to the ground and didn’t move his right arm. Team medical personnel attended to Harper before escorting him back to the dugout.
Harper was hit on the same arm he had Tommy John surgery on in November 2022 after leading Philadelphia to the 2022 World Series. He missed the first month-plus of the 2023 season before he came back in May, marking the fastest return on record by a MLB who underwent Tommy John surgery (160 days).
He was replaced Tuesday by Edmundo Sosa, who moved to third base the following inning with Alec Bohm moving from third to first base for Harper.
The Phillies said Harper suffered a right elbow contusion and that X-rays for Harper were negative, according to several reports.
‘We’ll have to re-evaluate in the morning, but the X-rays were negative. He was certainly in a lot of pain,’ Phillies manager Rob Thomson said.
It’s currently unknown if Harper will miss any time, but it was a scary sight for a Philadelphia team that is rolling. The Phillies recently were on a nine-game win streak and entering Tuesday, their 34-19 record was the best in baseball. Harper has played a major role in that with a .267 batting average with eight home runs and 33 RBIs on the season.
This story has been updated with new information
Larisa Sprott of Sprott Money and Argo shares her thoughts on the gold and silver markets, saying she sees the ‘smart money’ continuing to gravitate toward these metals.
In her view, price dips present a chance to get in at lower levels.
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking skills and typically affects people in their mid-60s.
According to the Alzheimer’s Association, neurons in other areas of the brain also begin to deteriorate as Alzheimer’s disease gets worse, resulting in the loss of basic human functions and overall cognitive impairment.
This condition affects more than 7 million people in the US alone; it’s also the most common form of dementia and is the seventh leading cause of death in America. Treatments are available to alleviate Alzheimer’s disease symptoms, but there are currently none that affect the underlying causes of this neurodegenerative disease.
Alzheimer’s disease therapies that have been approved by the US Food and Drug Administration (FDA) include: rivastigmine by Novartis (NYSE:NVS); galantamine, developed by Janssen, a division of Johnson & Johnson (NYSE:JNJ); donepezil by Pfizer (NYSE:PFE); and memantine by AbbVie (NYSE:ABBV).
Since there is no cure for Alzheimer’s disease, death is often the result for patients as the ailment causes brain deterioration. And unfortunately, Alzheimer’s disease is rising in prevalence — a report from Grand View Research suggests that the global Alzheimer’s disease treatment market will be worth a significant US$15.57 billion by 2030 as more patients need treatment, and as more investments are made in biomarkers for diagnosis and drug development.
Market cap: US$18.43 billion
Share price: US$125.81
The first NASDAQ-listed Alzheimer’s drug company on this list is Massachusetts-based Biogen, a pioneer in the field of neuroscience. The firm is focused on developing, manufacturing and marketing therapies aimed at treating serious neurological, neurodegenerative, autoimmune and rare diseases.
The global biotechnology firm’s research areas include Alzheimer’s disease and dementia. However, the launch of Biogen’s FDA-approved Alzheimer’s disease drug Aduhelm faced a lot of pushback in 2022, both from the market and from Congress, over what was viewed as a hasty fast-track approval process and exorbitant costs to patients.
Biogen gave it another go with Leqembi (lecanemab-irmb), its amyloid-beta monoclonal antibody for the treatment of Alzheimer’s disease, which the FDA approved in 2023 under its accelerated approval pathway. The drug was jointly developed by Biogen and Tokyo-based pharmaceutical company Eisai (OTC Pink:ESALF,TSE:4523). It is for patients with mild cognitive impairment or mild dementia, and is the first drug shown to slow the progression of Alzheimer’s disease to win FDA approval.
In January 2025, Leqembi received another FDA approval, this time for intravenous maintenance dosing for early-stage Alzheimer’s. Later, in April, the European Commission granted Leqembi Marketing Authorization in the EU for the treatment of mild early-stage Alzheimer’s disease.
That same month, the FDA granted fast track designation to Biogen’s investigational tau-targeting therapy BIIB080 for the treatment of Alzheimer’s.
Biogen’s earnings report for Q1 shows that first quarter global in-market sales of Leqembi reached approximately US$96 million, including US in-market sales of approximately US$52 million.
Market cap: US$3.68 billion
Share price: US$21.98
Acadia Pharmaceuticals specializes in neuroscience and neuro-rare diseases. The biotech’s product portfolio includes the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis, as well as the first and only approved drug in the United States and Canada for the treatment of Rett syndrome.
Acadia’s clinical-stage pipeline includes drug candidates targeting Prader-Willi syndrome and Alzheimer’s disease psychosis.
The company expects to enroll its final patient in its RADIANT Phase 2 study of ACP-204 in Alzheimer’s disease psychosis by early 2026 and release topline data in mid-2026.
According to the company, there are currently no approved treatments for hallucinations and delusions associated with Alzheimer’s disease psychosis.
Market cap: US$642.85 million
Share price: US$7.53
Anavex Life Sciences is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative, neurodevelopmental and neuropsychiatric disorders, such as Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome and other central nervous system disorders.
Anavex’ lead drug candidate, Anavex 2-73 (blarcamesine), has successfully completed Phase 2a and a Phase 2b/3 clinical trials for Alzheimer’s disease.
In early January, the company announced positive topline safety and efficacy data from more than three years of continuous treatment with blarcamesine for early Alzheimer’s disease patients. Later that month, Anavex announced it had been issued a US patent for the treatment.
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
American Rare Earths Limited (ARR:AU) has announced ARR advances permitting at Cowboy State Mine
Download the PDF here.
Challenger Gold Limited (ASX: CEL) (‘CEL’ or the ‘Company’) is pleased to announce it has entered into an Investment Protection Agreement (“IPA” or “the Agreement”) with the Government of Ecuador for its 100% owned El Guayabo Project (“El Guayabo” or “the Project”). Under the terms of the IPA, the Government of Ecuador has granted CEL legal protections including stability of the regulatory framework, resolution of disputes through international arbitration, and protection of CEL’s investment.
The IPA covers US$75 million in investment from CEL encompassing expenditures from CEL’s initial acquisition of the project in 2019 and expenditure incurred until the end of 2027. It has an initial term of 8 years and is renewable. Key incentives and protections under the IPA include:
Commenting on the Investment Protection Agreement, CEL Managing Director, Mr Kris Knauer, said
“The completion of the Investment Protection Agreement is a significant development for the Project..
The IPA provides certainty with respect to the legal framework governing the Project, including stable mining regulations and fiscal terms, and security of title and investment for the term of the agreement. Additionally, it provides protection from all forms of confiscation and a mechanism for international arbitration should there be any disputes related to the project.
The IPA is also timely given recent corporate action in Ecuador as we take steps to monetise our Ecuador assets following the significant resource upgrade from 4.5 million ounce1 to 9.1 million ounces1,2,3.‘
Click here for the full ASX Release